

**ASX / MEDIA RELEASE**

**17 JUNE 2019**

**Cochlear advises of FDA approval for Nucleus® Profile™ Plus Series implant**

Sydney, 17 June 2019 (ASX:COH): Cochlear Limited today advises it has received FDA approval for the Nucleus® Profile™ Plus Series cochlear implant and will commence an immediate US launch.

For further information, please contact:

**Analysts**

Kristina Devon  
Head of Investor Relations  
Email: [kdevon@cochlear.com](mailto:kdevon@cochlear.com)  
Ph: + 61 2 9611 6691

**Media**

Jennifer Stevenson  
Head of Corporate Communications  
Email: [jstevenson@cochlear.com](mailto:jstevenson@cochlear.com)  
Ph: +61 2 9611 6959